Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by Inspire Investing LLC from Q1 2018 to Q1 2025

Cintas cash flow from investing activities for the twelve months ending February 28, 2025 was $-1.546B, a 15.06% increase year-over-year. Cintas annual cash flow from investing activities for 2024 was $-0.609B, a 56.59% increase from 2023. Cintas annual cash flow from investing activities for 2023 was $-0.389B, a 3.47% decline from 2022. Cintas annual cash flow from investing activities for 2022 was $-0.403B, a 193.43% increase from 2021.

This statistic displays the share of France-based hedge funds as of December 2016, by top level strategy. As of December 2016, 25 percent of France-based hedge funds had an equity based strategy. Multi and managed futures/CTA strategies made up 17 percent and 15 percent of strategy approaches for France-based hedge funds respectively.

Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by CAPSTONE INVESTMENT ADVISORS LLC from Q3 2015 to Q1 2025

Coronary CTA AI Analysis Market Outlook

As per our latest research, the global Coronary CTA AI Analysis market size is valued at USD 698 million in 2024, demonstrating robust growth propelled by technological advancements and the increasing adoption of artificial intelligence in cardiovascular diagnostics. The market is experiencing a noteworthy compound annual growth rate (CAGR) of 17.4% from 2025 to 2033. By the end of 2033, the market is projected to reach an impressive USD 2.57 billion. This remarkable expansion is primarily driven by the rising prevalence of coronary artery disease, growing demand for non-invasive diagnostic tools, and the integration of AI-driven solutions to enhance the accuracy and efficiency of coronary computed tomography angiography (CTA) analysis.

One of the primary growth factors in the Coronary CTA AI Analysis market is the escalating global burden of cardiovascular diseases, especially coronary artery disease (CAD), which remains a leading cause of morbidity and mortality worldwide. With the World Health Organization estimating that cardiovascular diseases account for nearly 17.9 million deaths annually, there is a critical need for early and precise diagnostic modalities. Coronary CTA, augmented by advanced AI algorithms, offers clinicians a powerful tool for early detection and comprehensive assessment of coronary artery conditions. The integration of AI not only streamlines image interpretation but also reduces human error, enabling faster and more accurate clinical decision-making. This has led to increased adoption of AI-powered CTA solutions in both developed and emerging markets, further fueling market growth.

Another significant driver shaping the trajectory of the Coronary CTA AI Analysis market is the ongoing technological evolution in medical imaging and artificial intelligence. Over the past few years, AI and machine learning models have demonstrated superior performance in automating complex image analysis tasks, such as plaque characterization, stenosis quantification, and risk stratification. These advancements are enhancing the diagnostic value of coronary CTA, allowing for more nuanced and personalized patient assessments. Additionally, the integration of cloud-based platforms and advanced visualization tools is facilitating seamless data sharing, remote consultations, and multi-disciplinary collaboration—all of which are essential for modern healthcare delivery. As healthcare providers increasingly recognize the value of AI-enabled CTA analysis, investments in research and development are expected to accelerate, further propelling market expansion.

Moreover, the growing emphasis on preventive healthcare and the shift towards value-based care models are catalyzing the demand for Coronary CTA AI Analysis solutions. Healthcare systems across the globe are prioritizing early detection and risk assessment to reduce the economic and clinical burden of advanced coronary artery disease. AI-powered CTA analysis not only improves diagnostic accuracy but also optimizes workflow efficiency, enabling radiologists and cardiologists to manage larger patient volumes without compromising quality. This aligns with broader healthcare goals of improving patient outcomes, reducing hospital readmissions, and lowering overall costs. As reimbursement policies and regulatory frameworks evolve to support AI-driven diagnostics, the market is poised for sustained growth throughout the forecast period.

From a regional perspective, North America currently leads the Coronary CTA AI Analysis market, accounting for the largest share in 2024, followed closely by Europe and the Asia Pacific. The dominance of North America is attributed to a well-established healthcare infrastructure, high adoption rates of advanced imaging technologies, and the presence of major industry players. Europe is witnessing significant growth, driven by supportive government initiatives and increasing awareness of AI's benefits in cardiovascular care. Meanwhile, the Asia Pacific region is emerging as a lucrative market, supported by rapidly expanding healthcare systems, rising disposable incomes, and growing investments in digital health solutions. Collectively, these regional dynamics are shaping the global landscape of the Coronary CTA AI Analysis market.

The latest closing stock price for Cintas as of June 17, 2025 is 221.32. An investor who bought $1,000 worth of Cintas stock at the IPO in 1983 would have $1,388,328 today, roughly 1,388 times their original investment - a 18.80% compound annual growth rate over 42 years. The all-time high Cintas stock closing price was 227.66 on June 06, 2025. The Cintas 52-week high stock price is 229.24, which is 3.6% above the current share price. The Cintas 52-week low stock price is 172.20, which is 22.2% below the current share price. The average Cintas stock price for the last 52 weeks is 203.12. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.

The global market for Cased Telescoped Ammunition (CTA) is experiencing robust growth, driven by increasing demand from the defense sector for enhanced firepower and reduced weapon system weight. While precise market size figures for 2025 are unavailable, a reasonable estimation based on industry reports and observed trends suggests a market value of approximately $1.5 billion in 2025. Considering a conservative Compound Annual Growth Rate (CAGR) of 7% – reflective of the steady but significant advancements in CTA technology and ongoing military modernization efforts – the market is projected to reach approximately $2.5 billion by 2033. This growth is fueled by several key factors, including the ongoing adoption of CTA in armored vehicles and reconnaissance vehicles, the pursuit of lighter and more efficient weapon systems, and the increased focus on improving soldier lethality while reducing logistical burdens. The market segmentation highlights a strong preference for 45mm and 40mm calibers across various applications, suggesting a potential for specialized product development within these niches. Significant players like CTA International, BAE Systems, and Textron Systems are driving innovation and competition, further contributing to market expansion. The North American market currently holds a significant share, reflecting the region's substantial defense spending and technological advancements. However, the Asia-Pacific region is expected to witness substantial growth in the coming years due to increasing military investments and modernization initiatives in countries like China and India. Europe, while a mature market, remains a significant contributor due to ongoing defense procurements and collaborations among European nations. Restrictive regulations and the high initial investment costs associated with CTA adoption present challenges to market expansion. However, the long-term benefits of improved weapon performance and reduced logistical footprint are expected to outweigh these challenges, maintaining the upward trajectory of the CTA market throughout the forecast period. The continued development of more advanced CTA variants with improved accuracy, range, and reduced recoil will further fuel this growth.

Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by AIMZ Investment Advisors LLC from Q1 2015 to Q1 2025

The CTA dosimeter market is experiencing robust growth, driven by increasing demand across diverse sectors like healthcare, food processing, and research. The market size in 2025 is estimated at $2.5 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by stringent regulatory requirements for radiation safety, advancements in dosimeter technology offering improved accuracy and portability, and the expanding application of ionizing radiation in various fields. The high-dose range (10kGy-300kGy) segments within the CTA dosimeter market are expected to witness significant growth due to their crucial role in industrial sterilization processes and medical radiation therapy. The food and medical applications are the leading drivers, reflecting the increasing focus on food safety and the rising adoption of radiation therapy treatments globally. However, the market faces certain restraints, including the high initial investment costs associated with purchasing and maintaining CTA dosimeters, as well as the availability of alternative radiation monitoring techniques. Despite these challenges, the market outlook remains positive. The incorporation of advanced technologies such as wireless communication and data logging capabilities is enhancing the convenience and efficiency of CTA dosimeters. Furthermore, the growing awareness of radiation safety among professionals in various industries and government regulations promoting the use of reliable dosimeters contribute to the positive market trajectory. Leading players such as Fujifilm, Landauer, and Thermo Fisher Scientific are investing in research and development to improve product offerings and expand their market share. The Asia-Pacific region, particularly China and India, are poised for significant growth owing to rising industrialization and investment in healthcare infrastructure. The continued expansion of these factors, combined with technological advancements, indicates a sustained period of expansion for the CTA dosimeter market over the forecast period.

The global market for Animal-Specific Constant Temperature Amplification (CTA) Nucleic Acid Analyzers is experiencing robust growth, driven by increasing demand for rapid and accurate veterinary diagnostics, advancements in animal research, and a rising awareness of animal health globally. The market's expansion is fueled by several key factors. Firstly, the veterinary diagnostics segment is witnessing significant uptake of CTA technology due to its speed and portability, enabling faster disease detection and treatment, particularly in remote areas or during outbreaks. Secondly, the burgeoning field of animal research relies heavily on accurate and efficient nucleic acid analysis, leading to increased adoption of CTA analyzers for various research applications. Thirdly, government initiatives and investments in animal health infrastructure are further stimulating market growth. The market is segmented by application (Veterinary Diagnosis, Animal Research, Other) and by type (Pathogen Detection Analyzer, Genetic Marker Analyzer, Disease Specific Analyzer, Other). While precise market sizing data is unavailable, a reasonable estimate considering similar technologies and market growth rates puts the 2025 market value at approximately $250 million, projecting a Compound Annual Growth Rate (CAGR) of 15% over the forecast period (2025-2033). This robust CAGR reflects the aforementioned growth drivers and the increasing preference for CTA technology over traditional methods due to its enhanced speed, accuracy, and cost-effectiveness in specific applications. Challenges include high initial investment costs for advanced analyzers and the need for skilled personnel for operation and interpretation of results. However, continuous technological improvements and decreasing costs are likely to mitigate these restraints. The regional market is expected to be dominated by North America and Europe initially, due to established veterinary infrastructure and robust research funding. However, Asia-Pacific is projected to witness the fastest growth, driven by increasing veterinary expenditure, expanding research activities, and a growing awareness of animal health in developing economies such as China and India. Companies like Pluslife, CapitalBio, USTAR BIOTECHNOLOGIES (HANGZHOU), GegeReach Biotechnology, Jiangsu Qitian Gene Biotechnology, Hangzhou Bio Gener Technology, and GeneRadar Biotechnology are key players in the market, constantly innovating and expanding their product portfolios to cater to the growing demand for accurate and efficient animal-specific CTA nucleic acid analyzers. Competitive landscape is expected to remain dynamic with ongoing technological advancements and market consolidation through mergers and acquisitions.

Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by CONTRAVISORY INVESTMENT MANAGEMENT INC from Q3 2013 to Q2 2025

United Kingdom Hedge Fund Market was valued at USD 1.21 Trillion in 2024 and is expected to reach USD 1.80 Trillion by 2030 with a CAGR of 6.8% during the forecast period.

United States Hedge Fund Market was valued at USD 2.54 Trillion in 2024 and is expected to reach USD 3.56 Trillion by 2030 with a CAGR of 5.8% during the forecast period.

The global market for CTA Head and Neck Analysis Systems is experiencing robust growth, driven by the increasing prevalence of head and neck cancers, advancements in imaging technology offering improved diagnostic accuracy, and a rising demand for minimally invasive procedures. The market is segmented by application (public and private hospitals) and by type of test (tumor screening and vascular tests). Major players like Siemens, GE Healthcare, and Philips dominate the market, leveraging their established reputations and extensive distribution networks. However, the emergence of innovative companies such as Lianying Intelligent, Keya Medical, and SenseTime, particularly in the Asia-Pacific region, is introducing competitive pressures and fostering innovation in areas like AI-powered image analysis. The market's growth is further fueled by government initiatives promoting early cancer detection and improved healthcare infrastructure in developing economies. While high initial investment costs and the need for skilled professionals can pose challenges, the long-term benefits in terms of improved patient outcomes and reduced healthcare burdens are driving market expansion. The forecast period (2025-2033) anticipates continued growth, although the CAGR may fluctuate slightly due to economic factors and technological advancements. Regional variations are expected, with North America and Europe maintaining a substantial market share due to high healthcare expenditure and advanced medical infrastructure. However, the Asia-Pacific region, particularly China and India, is projected to witness significant growth owing to rising disposable incomes, a growing middle class, and increasing awareness regarding early cancer detection. The competitive landscape will remain dynamic, with existing players focusing on product innovation and strategic partnerships, while new entrants seek to carve out a niche through cost-effective solutions and specialized applications. Overall, the market for CTA Head and Neck Analysis Systems presents a promising investment opportunity for stakeholders, with substantial potential for expansion across multiple geographical regions and application segments.

Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by FAIRVIEW CAPITAL INVESTMENT MANAGEMENT LLC from Q3 2013 to Q1 2025

The Chain Transfer Agents (CTA) market, valued at $237.1 million in 2025, exhibits robust growth potential, projected to expand at a Compound Annual Growth Rate (CAGR) of 5.7% from 2025 to 2033. This growth is driven by the increasing demand across diverse applications, primarily in the consumer and industrial sectors, agrochemicals, polymers and rubber, and water treatment. The rising adoption of efficient polymerization techniques and the expanding use of plastics in various industries significantly fuel market expansion. Furthermore, the growing awareness of sustainable manufacturing practices and the development of environmentally friendly CTA alternatives contribute to market dynamism. Specific segments like mercaptans and trichloroethylene are experiencing significant traction due to their versatile applications and established market presence. However, stringent environmental regulations concerning the use of certain CTAs and the inherent toxicity associated with some chemical compounds pose significant challenges. This necessitates ongoing research and development focused on safer and more sustainable alternatives. The geographical distribution of the market shows strong growth in regions like Asia Pacific, particularly in countries such as China and India, driven by their robust industrialization and expanding manufacturing capabilities. North America and Europe, while mature markets, continue to contribute significantly to overall market value. The competitive landscape is characterized by the presence of major players like Arkema, BASF, and others, each striving to enhance their product portfolios and expand their geographical reach. The strategic partnerships and collaborations among these companies aim to leverage technological advancements and capitalize on emerging market opportunities. The next decade is likely to witness further consolidation within the CTA market, as companies invest in research and development to offer innovative and environmentally sustainable solutions. The market's future trajectory hinges upon successfully addressing environmental concerns and continuously innovating to meet the ever-evolving demands of diverse industrial sectors. The projected market size in 2033, estimated based on the provided CAGR, anticipates significant expansion.

Cellulose Triacetate Optical Film Market Outlook

As per our latest research, the global cellulose triacetate optical film market size reached USD 1.32 billion in 2024, reflecting robust demand across various end-use industries. The market is expected to grow at a CAGR of 5.9% from 2025 to 2033, projecting a value of approximately USD 2.23 billion by 2033. This growth is primarily driven by the expanding applications of cellulose triacetate (CTA) optical films in advanced display technologies, particularly in the consumer electronics and automotive sectors. The surge in demand for high-performance display panels and the continuous innovation in optical films are the key growth factors shaping the market landscape in the coming years.

The primary growth driver for the cellulose triacetate optical film market is the rapidly increasing penetration of display technologies in consumer electronics. The proliferation of smartphones, tablets, laptops, and advanced televisions has necessitated the use of high-quality optical films to enhance display clarity, contrast, and durability. CTA films, known for their excellent optical transparency, dimensional stability, and heat resistance, are widely used in polarizer and protective films for LCD panels. Additionally, the ongoing shift towards OLED and flexible displays in premium devices is further fueling the demand for innovative optical film solutions. Manufacturers are investing in research and development to improve the performance characteristics of CTA films, enabling their integration into next-generation display panels and reinforcing their critical role in the electronics value chain.

Another significant factor propelling market growth is the increasing adoption of cellulose triacetate optical films in the automotive sector. Modern vehicles are increasingly equipped with digital instrument clusters, infotainment systems, and head-up displays, all of which require high-performance optical films to ensure clear visibility and resistance to environmental stressors. The automotive industry’s focus on enhanced driver experience, safety, and in-cabin aesthetics has accelerated the use of CTA-based films in various optical components. Furthermore, the growing trend of electric vehicles and autonomous driving technologies is expected to intensify the need for advanced display solutions, thereby augmenting the demand for cellulose triacetate optical films across automotive applications.

Sustainability concerns and regulatory pressures are also contributing to the market’s expansion. Cellulose triacetate, derived from renewable cellulose sources, offers a more environmentally friendly alternative to petroleum-based optical films. As regulatory frameworks tighten around the use of hazardous materials and carbon emissions, manufacturers and end-users are increasingly turning to sustainable materials like CTA. This shift is particularly prominent in regions with stringent environmental regulations, such as Europe and parts of Asia Pacific. The market’s alignment with global sustainability trends not only enhances its growth prospects but also positions cellulose triacetate optical films as a preferred choice in industries seeking to minimize their ecological footprint.

From a regional perspective, Asia Pacific continues to dominate the global cellulose triacetate optical film market, accounting for the largest share in 2024. This is largely attributed to the presence of major electronics manufacturing hubs in countries like China, Japan, and South Korea. The region benefits from a well-established supply chain, significant investments in display technology, and strong demand from both consumer electronics and automotive industries. North America and Europe also represent substantial markets, driven by technological advancements and a focus on sustainability. Meanwhile, Latin America and the Middle East & Africa are witnessing gradual growth, supported by increasing adoption of digital technologies and expanding industrial bases. The regional outlook underscores the global nature of demand for cellulose triacetate optical films, with Asia Pacific poised to maintain its leadership throughout the forecast period.

Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by CONTRAVISORY INVESTMENT MANAGEMENT INC from Q3 2013 to Q1 2025

Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for CTAS held by BRIDGES INVESTMENT MANAGEMENT INC from Q3 2019 to Q1 2025